Complix NV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Complix NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10577
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Complix NV (Complix) is a biopharmaceutical company that discovers and develops alphabodies and pre-clinical programs. The company’s products comprise CMPX-1023, a novel alphabody for autoimmune diseases, and cell penetrating alphabodies for the treatment of cancer, among others. It designs and develops CPABs to address intracellular targets including protein-protein interactions, among others. Complix designs CMPX-1023 to antagonize IL-23, a cytokine that plays a central role in the inflammatory process of types of severe autoimmune diseases. The company also provides evaluation and development of its alphabody protein technology in agriculture, among others. It has its operations in Belgium and Luxemborg. Complix is headquartered in Diepenbeek, Belgium.

Complix NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Complix NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Complix NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Complix NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Complix NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Complix NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Complix NV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Complix Raises US$15.5 Million In Series B Financing 10
Partnerships 12
Complix Expands Agreement with Merck 12
Complix Partners with Selexis 13
Complix NV – Key Competitors 14
Complix NV – Key Employees 15
Complix NV – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Government and Public Interest 17
Dec 14, 2017: Complix Receives €0.5 Million Grant to Further Develop its Pipeline of Proprietary Cell Penetrating Alphabodies™ Against Intracellular Cancer Targets 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Complix NV, Pharmaceuticals & Healthcare, Key Facts 2
Complix NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Complix NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Complix NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Complix NV, Deals By Therapy Area, 2012 to YTD 2018 8
Complix NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Complix Raises US$15.5 Million In Series B Financing 10
Complix Expands Agreement with Merck 12
Complix Partners with Selexis 13
Complix NV, Key Competitors 14
Complix NV, Key Employees 15
Complix NV, Other Locations 16
Complix NV, Subsidiaries 16

List of Figures
Complix NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Complix NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Complix NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Complix NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Complix NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Complix NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Complix NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Complix NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Complix NV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Transocean Ltd.:戦略・SWOT・企業財務分析
    Transocean Ltd. - Strategy, SWOT and Corporate Finance Report Summary Transocean Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • CITIC Securities Company Limited:企業の戦略・SWOT・財務分析
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Bank of Chongqing Co Ltd:企業の戦略・SWOT・財務分析
    Bank of Chongqing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank of Chongqing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Baylor Scott & White Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Baylor Scott & White Health (Baylor Scott & White) is a not-for-profit healthcare service provider that offers medical care services. The organization offers medical education, medical services and conducts medical research. It offers medical services in the areas of emergency care, cancer c …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Aiphone Co Ltd (6718):企業の財務・戦略的SWOT分析
    Aiphone Co Ltd (6718) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Provogue (India) Limited (PROVOGE):企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-医療機器分野:企業M&A・提携分析
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University's researchers and students. The company’s products include exelon, doxil, cherry tomatoes and lo …
  • Dynegy Inc.:戦略・SWOT・企業財務分析
    Dynegy Inc. - Strategy, SWOT and Corporate Finance Report Summary Dynegy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Sarossa plc-製薬・医療分野:企業M&A・提携分析
    Summary Sarossa plc (Sarossa), formerly Sarossa Capital Limited, is an investment holding and management company. The company principally makes investment in and growth and development of businesses which present opportunities for value creation. It focuses on portfolio investment in major internati …
  • Gammon India Ltd (GAMMONIND):企業の財務・戦略的SWOT分析
    Gammon India Ltd (GAMMONIND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hycrete Inc:企業の戦略的SWOT分析
    Hycrete Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Cineworld Group Plc:企業の戦略・SWOT・財務情報
    Cineworld Group Plc - Strategy, SWOT and Corporate Finance Report Summary Cineworld Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • The AES Corporation:企業の戦略・SWOT・財務情報
    The AES Corporation - Strategy, SWOT and Corporate Finance Report Summary The AES Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • GRI Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary GRI Bio Inc (GRI Bio) is a biotech company that develops and manufactures therapies for inflammatory diseases. The company develops Natural Killer T cell based therapies for the treatment of liver disease and autoimmune disoders. Its lead candidate GRI-0621, a novel oral therapeutic for live …
  • Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析
    Summary Erytech Pharma SA (ERYTECH Pharma) is a clinical-stage biopharmaceutical company developing red blood cell-based therapeutics for cancer and orphan diseases. Its pipeline product candidates include erymethionase (methionine-?-lyase), a novel amino acid agent targeting cancer metabolism in so …
  • BDO International Ltd:企業の戦略的SWOT分析
    BDO International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Coherus BioSciences Inc (CHRS):企業の財務・戦略的SWOT分析
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • Lidds AB (LIDDS):企業の財務・戦略的SWOT分析
    Summary Lidds AB (Lidds) is a developer of pharmaceutical products for the treatment of cancer and other diseases. The company offers Liproca Depot, an injectable product used for the treatment of prostate cancer. Its Liproca is a bioresorbable, biocompatible and locally injectable modified release …
  • Volt Information Sciences Inc (VOLT):企業の財務・戦略的SWOT分析
    Volt Information Sciences Inc (VOLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆